INFO & CONTACTS:  +39 02 2390 1

A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02)

Phase: Phase II-III clinical trials

Principal Investigator: Dott.ssa Verzoni Elena

Main Facility: Oncologia Medica Genitourinaria

Drug: Saruparib (AZD5305)

Pathologies: Prostate tumors

The purpose of the study is to evaluate the impact on metastases-free survival with the addition of saruparib versus placebo to a standard RT + ADT regimen in men with high-risk and very high-risk (localised/locally advanced) prostate cancer with a BRCAm.  

Study details include:  

  • The study will be performed in approximately 300 centres in approximately 26 countries (including the US, EU, China, and Japan) 
  • The enrolment period will be up to approximately 56 months 
  • Participants must be eligible for randomisation within 10 months of initial diagnosis (either de novo or BCR) 
  • The study treatment duration with saruparib/placebo will be 24 months 
  • The visit frequency during the treatment period will be every 4 weeks. 

Randomised participants will continue treatment with saruparib/placebo in combination with ADT until disease progression, unacceptable toxicity occurs, or if the participant requests to stop the study intervention.

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe